Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q2 2022 · 10-Q
Revenue$45.00K$45.00K−83.1% vs Q2 2021 Net Income-$7.77M-$7.77MN/M vs Q2 2021 EPS Diluted-$0.33-$0.33N/M vs Q2 2021 Operating Income-$7,850,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$27,648,000N/M Margins · derivedOperating margin-17444.4%−15536.5 pt vs Q2 2021
Net margin-17260.0%−15372.4 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 12, 2022 · 43 d after period end